Ken Griffin Clearside Biomedical, Inc. Call Options Transaction History

Citadel Advisors LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$1.08 - $1.58 $9,828 - $14,378	9,100 Added 107.06%	17,600 $22,000
Q2 2023 Aug 14, 2023	SELL	$0.97 - $1.48 $8,439 - $12,876	-8,700 Reduced 50.58%	8,500 $9,000
Q1 2023 May 15, 2023	SELL	$0.93 - $1.66 $10,230 - $18,260	-11,000 Reduced 39.01%	17,200 $17,000
Q4 2022 Feb 14, 2023	SELL	$1.0 - $1.5 $7,500 - $11,250	-7,500 Reduced 21.01%	28,200 $31,000
Q3 2022 Nov 14, 2022	SELL	$1.08 - $1.83 $8,964 - $15,189	-8,300 Reduced 18.86%	35,700 $40,000

13.4M

17.6K

100

Ticker CLSD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,190,700
Market Cap $78.2M
Description
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injec...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.